Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.39 USD | -0.62% | +23.60% | +334.69% |
11/04 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
11/04 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 188M 15.64B |
---|---|---|---|---|---|
Net income 2024 * | -41M -3.42B | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.02
x | P/E ratio 2025 * |
-
| Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.01% |
1 day | -0.62% | ||
1 week | +23.60% | ||
Current month | +304.43% | ||
1 month | +314.94% | ||
3 months | +430.29% | ||
6 months | +610.16% | ||
Current year | +334.69% |
Managers | Title | Age | Since |
---|---|---|---|
Paul-Peter Tak
CEO | Chief Executive Officer | 64 | 01/20/01 |
Founder | 66 | 01/02/01 | |
Charles Schoch
DFI | Director of Finance/CFO | 39 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Papa
BRD | Director/Board Member | 68 | 08/22/08 |
Edward Benz
BRD | Director/Board Member | 78 | 01/17/01 |
Paul Manning
CHM | Chairman | 68 | 01/18/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 6.39 | -0.62% | 391,978 |
25/24/25 | 6.43 | +6.28% | 750,648 |
24/24/24 | 6.05 | +2.37% | 672,175 |
23/24/23 | 5.91 | +6.68% | 462,336 |
22/24/22 | 5.54 | +7.16% | 581,998 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+334.69% | 188M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CADL Stock